Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268723 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT00268723 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 15 participants.
The verdict
NCT00268723, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
To determine if administration of levalbuterol tartrate HFA MDI in subjects with EIB will be effective in the prevention of EIB and be safe and well-tolerated.
Interventions
- DRUG Placebo
- DRUG Levalbuterol tartrate HFA MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268723
The ClinicalTrials.gov registry entry for NCT00268723 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00268723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00268723 about?
NCT00268723 is a clinical study titled "Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB". To determine if administration of levalbuterol tartrate HFA MDI in subjects with EIB will be effective in the prevention of EIB and be safe and well-tolerated.
What is the current status of trial NCT00268723?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2005-12. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00268723?
The interventions under investigation include: Placebo (DRUG), Levalbuterol tartrate HFA MDI (DRUG).
Who is sponsoring clinical trial NCT00268723?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.